Third Harmonic Bio (THRD) shares rose 40% in recent Monday premarket activity, after saying its board has approved a plan for the company's liquidation and dissolution and will seek stockholder approval for the plan at its annual meeting on June 5.

Verve Therapeutics (VERV) stock climbed 23% after it reported positive initial results from its phase 1b Heart-2 clinical study to evaluate gene editing therapy VERVE-102 for patients with heterozygous familial hypercholesterolemia and premature coronary artery disease.

Palatin Technologies (PTN) shares were up 22% after the biopharmaceutical company said it appealed the New York Stock Exchange's decision to delist its common shares.

Apple (AAPL) shares rose 6.4% after KeyBanc upgraded it to sector weight from underweight, followed by a Counterpoint Research report saying that the tech giant was Q1's top seller in the global smartphone market with a 19% market share, aided by the launch of the iPhone 16e and continued growth in its non-core markets.

BP (BP) stock gained more than 3% after the energy giant said it has made an oil discovery at the Far South prospect in deep water in the 'Gulf of America.'